Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 43Breast 13Genitourinary 11Myeloid 10Plasma cell 9Classical hematology 9Thoracic 8Gynecologic 8Head & Neck 5Tumor-Agnostic 4Other neoplasm 3Dermatologic 3Sarcoma 2Other hematologic neoplasm 2CNS 2Other solid neoplasm 1Other 1Lymphoid 1

Conditions

Melanoma 3

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Aspirin × Dermatologic × Clear all
NCT03396952 2022-10-13

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

University of California, San Francisco

Phase 2 Completed
27 enrolled 13 charts
Dermatologic

Melanoma

NCT04062032 2022-02-18

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

University of Utah

Phase 2 Completed
41 enrolled
Dermatologic

Melanoma

NCT04066725 2022-02-18

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

University of Utah

Phase 2 Completed
95 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡